Table 2.
Neutralising potency of clinically relevant monoclonal antibodies against the SARS-CoV-2 omicron (B.1.1.529) variant
| D614G IC50 (μg/mL) | Omicron IC50 (μg/mL) | Fold change in IC50 (omicron vs D614G) | Mutations* | |
|---|---|---|---|---|
| Casirivimab (REGN-10933)7 | 0·009 | >10 | >1100 | 417†, 484†, 493†, 477, 478 |
| Imdevimab (REGN-10987)7 | 0·008 | >10 | >1200 | 440†, 446† |
| Bamlanivimab (LY-CoV555)8 | 0·007 | >10 | >1400 | 484†, 493†, 478 |
| Etesevimab (LY-CoV16)8 | 0·04 | >10 | >270 | 417†, 493, 501, 505, 477 |
| Sotrovimab (S309)9 | 0·1 | 0·2 | 2 | 339 |
IC50=50% inhibitory concentration.
*
Mutated amino acid positions modelled on the omicron receptor binding domain, proximal to the antibody interface, are listed.
†
Functional evidence (from deep mutational scanning data13) for an effect on antibody binding of mutations at that amino acid position.